breast cancer - triple negative | |
es-BC - TNBC - NA - all population | |
atezolizumab plus carboplatin plus nab-paclitaxel | NeoTRIPaPDLA |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -